



ATTRIBUTION 4.0 INTERNATIONAL

Deed

Canonical URL :

<https://creativecommons.org/licenses/by/4.0/>

[See the legal code](#)

You are free to:

Share — copy and redistribute the material in any medium or format for any purpose, even commercially.

Adapt — remix, transform, and build upon the material for any purpose, even commercially.

The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

Attribution — You must give **appropriate credit**, provide a link to the license, and **indicate if changes were made**. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

No additional restrictions — You may not apply legal terms or **technological measures** that legally restrict others from doing anything the license permits.

Notices:

You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable **exception or limitation**.

No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as **publicity, privacy, or moral rights** may limit how you use the material.

Notice

This deed highlights only some of the key features and terms of the actual license. It is not a license and has no legal value. You should carefully review all of the terms and conditions of the actual license before using the licensed material.

Creative Commons is not a law firm and does not provide legal services.

Distributing, displaying, or linking to this deed or the license that it summarizes does not create a lawyer-client or any other relationship.

Creative Commons is the nonprofit behind the open licenses and other legal tools that allow creators to share their work. Our legal tools are free to use.

- [Learn more about our work](#)
- [Learn more about CC Licensing](#)
- [Support our work](#)
- [Use the license for your own material.](#)
- [Licenses List](#)
- [Public Domain List](#)

Footnotes

appropriate credit — If supplied, you must provide the name of the creator and attribution parties, a copyright notice, a license notice, a disclaimer notice, and a link to the material. CC licenses prior to Version 4.0 also require you to provide the title of the material if supplied, and may have other slight differences.

- [More info](#)

indicate if changes were made — In 4.0, you must indicate if you modified the material and retain an indication of previous modifications. In 3.0 and earlier

license versions, the indication of changes is only required if you create a derivative.

- [Marking guide](#)
- [More info](#)

technological measures — The license prohibits application of effective technological measures, defined with reference to Article 11 of the WIPO Copyright Treaty.

- [More info](#)

exception or limitation — The rights of users under exceptions and limitations, such as fair use and fair dealing, are not affected by the CC licenses.

- [More info](#)

publicity, privacy, or moral rights — You may need to get additional permissions before using the material as you intend.

- [More info](#)

Contact Newsletter Privacy Policies Terms

CONTACT US

Creative Commons PO Box 1866,
Mountain View, CA 94042

info@creativecommons.org

[+1 415 429 6753](tel:+14154296753)

SUBSCRIBE TO OUR NEWSLETTER

You

SUBSCRIBE

SUPPORT OUR WORK

Our work relies on you!
Help us keep the
Internet free and open.

DONATE NOW

Except where otherwise **noted**, content on this site is licensed under a **Creative Commons Attribution 4.0 International license**.

Icons by **Font Awesome**.




Figure 1 B7 homolog 3. A: Regulation of B7 homolog 3 (B7-H3) expression and its immunological and nonimmunological tumor-promoting molecular mechanisms; B: Role of B7-H3 in T cell activation. Although some studies recognize B7-H3 as a costimulatory molecule, most available data evidence its coinhibitory role. The B7-H3 receptor(s) is still unknown. Three possible receptors have been suggested to date, namely triggering receptor expressed on myeloid cells-like transcript 2 possibly conducting costimulatory signal, and interleukin 20 receptor subunit alpha, and phospholipase A2 receptor 1

possibly conducting coinhibitory signal. Akt: Protein kinase B; APC: Antigen-presenting cell; B7-H3: B7 homolog 3; CD276: Cluster of differentiation 276, chr: Chromosome; HIF- α : Hypoxia-inducible factor 1-alpha; IFN- γ : Interferon-gamma; IgC: Immunoglobulin constant region; IgV: Immunoglobulin variable region; IL-2: Interleukin-2; IL-10: Interleukin-10; IL-13: Interleukin-13; JAK: Janus kinase; MAPK: Mitogen-activated protein kinase, MEK: MAPK kinase; miRNAs: MicroRNAs; MMPs: Matrix metalloproteinases; mTOR: Mammalian target of rapamycin; NF- κ B: Nuclear factor-kappa B; PI3K: Phosphatidylinositol 3-kinase; STAT: Signal transducer and activator of transcription; VEGF: Vascular endothelial growth factor; MHC: Major histocompatibility complex; TCR: T cell receptor. This Figure was partly generated using Servier Medical Art, provided by Servier (https://smart.servier.com/smart_image/), licensed under a Creative Commons Attribution 4.0 unported license (<https://creativecommons.org/licenses/by/4.0/>).